15
Participants
Start Date
July 21, 2017
Primary Completion Date
October 31, 2023
Study Completion Date
November 2, 2023
Tadekinig alfa
Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
0.9% sodium chloride
To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
Children Hospital of Philadelphia, Philadelphia
Children's Healthcare of Atlanta at Egleston, Atlanta
Cincinnati Children's Hospital Medical Center, Cincinnati
Texas Children's Hospital _ Baylor College of Medicine, Houston
Universitätsklinikum Freiburg, Centrum für Chronische Immundefizienz (CCI) - Paediatric Unit, Freiburg im Breisgau
UCSD _ Department of Pediatrics / Rady Children's Hospital, La Jolla
Boston Children's Hospital, Boston
The Hospital for Sick Children, Toronto
CHU Sainte-Justine, Montreal
Lead Sponsor
AB2 Bio Ltd.
INDUSTRY